Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Travere Therapeutics, Inc. < Previous 1 2 Next > Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals September 05, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers MIRM TVTX Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference August 31, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 August 24, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Second Quarter 2023 Financial Results August 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report Second Quarter 2023 Financial Results July 20, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals July 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers MIRM TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 June 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at Upcoming Investor Conferences June 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria May 31, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports First Quarter 2023 Financial Results May 04, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis May 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report First Quarter 2023 Financial Results April 26, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 April 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at Upcoming Investor Conferences March 28, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 March 23, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 March 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares March 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants February 28, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Proposed Public Offering of Common Stock February 27, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results February 23, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results February 16, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at Upcoming Investor Conferences February 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.